Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CES 2022: Defying Omicron, World’s Biggest Tech Show Goes Live In Las Vegas

Executive Summary

CES 2022 is missing some marquee names due to the coronavirus surge, but there’s still plenty to take in at the intersection of digital health and consumer tech. In this roundup, Medtech Insight highlights some standouts, with commentary from company leaders.

You may also be interested in...



FDA Draft Guidance Paves Way For Collecting Clinical Study Data Via Digital Health Technologies

The US FDA released draft guidance on how device makers, investigators and other stakeholders can use digital health solutions to collect data from clinical study participants remotely. Comments are due to the agency by 22 March 2022.

‘Training People To Be Healthier’: Digital Therapeutics Programmed For Growth

Experts foresee the digital therapeutics market growing to $6bn-$9bn by 2025, driven in part by tech-empowered consumers and patients looking for solutions to better manage their own health and conditions. For medtechs, collaborations with software-driven start-ups will be key to harnessing personalized data and differentiating themselves in the marketplace.

Financing Quarterly Statistics: Q1 Highlights Include 3 Medtech And 7 IVD IPOs

To open the year, medical device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $7bn.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT144910

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel